Advertisement
Singapore markets close in 2 hours 52 minutes
  • Straits Times Index

    3,298.32
    -15.73 (-0.47%)
     
  • Nikkei

    38,979.25
    -90.43 (-0.23%)
     
  • Hang Seng

    19,250.85
    -385.37 (-1.96%)
     
  • FTSE 100

    8,424.20
    +3.94 (+0.05%)
     
  • Bitcoin USD

    71,200.07
    +4,099.88 (+6.11%)
     
  • CMC Crypto 200

    1,526.75
    +38.21 (+2.57%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • Dow

    39,806.77
    -196.82 (-0.49%)
     
  • Nasdaq

    16,794.88
    +108.91 (+0.65%)
     
  • Gold

    2,420.60
    -17.90 (-0.73%)
     
  • Crude Oil

    79.22
    -0.58 (-0.73%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • FTSE Bursa Malaysia

    1,624.47
    -3.03 (-0.19%)
     
  • Jakarta Composite Index

    7,227.92
    -38.77 (-0.53%)
     
  • PSE Index

    6,625.88
    -56.90 (-0.85%)
     

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, May 9th @ 4:30 PM ET

Domestic:

1-888-886-7786

International:

1-416-764-8658

Conference ID:

71864759

 

 

Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.

ADVERTISEMENT

Call me™: https://emportal.ink/3xjDV8X

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1664624&tp_key=4756f5f4c0

About Crinetics Pharmaceuticals 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, first-in-class, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.

Contact:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
858 345-6075

Source: Crinetics Pharmaceuticals, Inc.